跳至主要内容
临床试验/NCT03317951
NCT03317951Unknown不适用

A Randomized Controlled Trial for Investigating a Novel Integrated Care Concept (NICC) for Patients Suffering From Chronic Cardiovascular Disease: CardioCare MV

University Medical Center Rostock1 个研究点 分布在 1 个国家目标入组 964 人开始时间: 2017年12月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
964
试验地点
1
主要终点
Composite endpoint death and cardiovascular events

研究概览

简要总结

Cardiovascular diseases are the number 1 cause of death globally and represent a major economic burden on health care systems. The investigators have developed a novel integrated care concept (NICC) which combines telemedicine with intensive support by a call center, an integrated care network including in- and outpatient care providers and guideline therapy for patients with heart failure (HF), atrial fibrillation (AF) or therapy resistant hypertension (TRH). The aim of the study is to show that NICC is preferable over guideline therapy alone. We aim at including approximately 890 patients. Patients could be enrolled either directly at the Care-Center (location: University Hospital of Rostock) or at one of the advanced treatments rooms of the Care-Center (outpatient cardiological specialist practices).

The ethics commission's statement of the University of Rostock is available for amendment 2 since 20.08.2019 at the number A2017-0117.

详细描述

Background: Cardiovascular diseases are the number 1 cause of death globally and represent a major economic burden on health care systems. Positive effects of disease management programs have been shown for patients with heart failure (HF). Remote monitoring and telemonitoring with active intervention are beneficial in atrial fibrillation (AF) and therapy resistant hypertension (TRH), respectively. For these patients, the investigators have developed a novel integrated care concept (NICC) which combines telemedicine with intensive support by a call center, an integrated care network including in- and outpatient care providers and guideline therapy for patients.

Methods: The aim of the study is to demonstrate the superiority of NICC over guideline therapy alone. The trial is designed as open-label bi-center parallel-group design with two groups. Patients will be included if they are either inpatients or if they are referred to the outpatient clinic of the hospitals by their treating physician. Randomization will be done individually with stratification by cardiovascular disease (AF, HF, TRH), center and admission type. Primary endpoints are based on the 1-year observation period after randomization. The first primary endpoint is the composite endpoint consisting of mortality, stroke and myocardial infarction. The number of hospitalizations form the second primary endpoint. The third primary endpoint is identical to the first primary endpoint plus cardiac decompensation. Adjustments for multiple testing are done using a fall back strategy. Secondary endpoints include patient adherence, health care costs, quality of life and safety. The power for the second primary endpoint is 80% at the two-sided 2.5% test-level with a sample size of 890 patients.

Discussion: This study will inform care providers whether quality of care can be improved by an integrated care concept providing telemedicine through a 24/7 care center approach. We expect that cost of the NICC will be lower than standard care because of reduced hospitalizations. If the study has a positive result, NICC is planned to be immediately rolled out in the state of Mecklenburg-West Pomerania. The trial will also guide additional research to disentangle the effects of this complex intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Heart failure (I50, NYHA II-IV) or atrial fibrillation (I48, EHRA II-IV) or resistant hypertension (I10-15, ≥ 3 antihypertensive medicines from different drug classes, SBP > 140 /90mmHg or ≥ 4 antihypertensives irrespective of the blood pressure, with at least one drug being a diuretic).
  • Member of health insurance company AOK Nordost or Techniker Krankenkasse (TK).
  • Inscription to integrated care contract with the health insurance company.
  • Residence in Mecklenburg-Vorpommern.
  • Age ≥ 18 years.
  • Written informed consent.

排除标准

  • Pregnancy, suspected pregnancy or breast-feeding period.
  • Participation in another clinical trial up to 30 days before inclusion in this trial.
  • Cognitive deficits: patients need to be able to read and understand German language as presented on a tablet.
  • Chronic kidney disease requiring dialysis or creatinine clearance < 15 ml/min.

结局指标

主要结局

Composite endpoint death and cardiovascular events

时间窗: 1-year after randomization

Composite endpoint consisting of mortality (occurrence: yes/no), stroke (yes/no) and myocardial infarction (yes/no) within the 1-year observation period. Endpointed rated as yes if at least one yes

Hospitalization

时间窗: 1-year after randomization

Number of hospitalizations within the 1-year observation period

Composite endpoint death and broader cardiovascular events

时间窗: 1-year after randomization

Composite endpoint consisting of mortality (occurrence: yes/no), stroke (yes/no), myocardial infarction (yes/no) and cardiovascular decompensation (yes/no) within the 1-year observation period. Endpointed rated as yes if at least one yes.

次要结局

  • Time to event(1-year after randomization)
  • Adherence to novel integrated care concept(1-year after randomization)
  • Quality of life(Baseline, 6 months, 1 year)
  • Safety as measured by cardiovascular events(1-year after randomization)
  • Beliefs about medicine questionnaire(Baseline, 6 months, 1 year)
  • Cost(1-year after randomization)
  • Patient activation measure(Baseline, 6 months, 1 year)
  • Generalized Anxiety Disorder scale(Baseline, 6 months, 1 year)
  • Medication adherence report scale(Baseline, 6 months, 1 year)
  • Illness-specific Social Support Scale Short version-8(Baseline, 6 months, 1 year)
  • Heart specific quality of life(Baseline, 6 months, 1 year)
  • Patient Health Questionnaire depression module(Baseline, 6 months, 1 year)
  • World Health Organization Well-Being Index(Baseline, 6 months, 1 year)

研究者

发起方
University Medical Center Rostock
申办方类型
Other
责任方
Principal Investigator
主要研究者

Christian Schmidt

Ärztlicher Vorstand

University of Rostock

研究点 (1)

Loading locations...

相似试验

Investigation of a Novel Integrated Care Concept... | 临床试验